200 related articles for article (PubMed ID: 23554889)
1. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.
Shao L; Zhou Z; Cai Y; Castro P; Dakhov O; Shi P; Bai Y; Ji H; Shen W; Wang J
PLoS One; 2013; 8(3):e58391. PubMed ID: 23554889
[TBL] [Abstract][Full Text] [Related]
2. Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis.
Zhang L; Shao L; Creighton CJ; Zhang Y; Xin L; Ittmann M; Wang J
Oncotarget; 2015 Mar; 6(8):6281-94. PubMed ID: 25749044
[TBL] [Abstract][Full Text] [Related]
3. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.
Semaan L; Mander N; Cher ML; Chinni SR
BMC Cancer; 2019 Oct; 19(1):972. PubMed ID: 31638934
[TBL] [Abstract][Full Text] [Related]
5. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
[TBL] [Abstract][Full Text] [Related]
6. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
Shao L; Tekedereli I; Wang J; Yuca E; Tsang S; Sood A; Lopez-Berestein G; Ozpolat B; Ittmann M
Clin Cancer Res; 2012 Dec; 18(24):6648-57. PubMed ID: 23052253
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
8. Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4.
Wang J; Cai Y; Shao LJ; Siddiqui J; Palanisamy N; Li R; Ren C; Ayala G; Ittmann M
Cancer Res; 2011 Feb; 71(4):1325-33. PubMed ID: 21169414
[TBL] [Abstract][Full Text] [Related]
9. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
[TBL] [Abstract][Full Text] [Related]
10. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.
Washington MN; Weigel NL
Endocrinology; 2010 Apr; 151(4):1409-17. PubMed ID: 20147525
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.
Li Y; Kong D; Wang Z; Ahmad A; Bao B; Padhye S; Sarkar FH
Cancer Prev Res (Phila); 2011 Sep; 4(9):1495-506. PubMed ID: 21680704
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
Cai C; Wang H; Xu Y; Chen S; Balk SP
Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
[TBL] [Abstract][Full Text] [Related]
13. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.
Ratz L; Laible M; Kacprzyk LA; Wittig-Blaich SM; Tolstov Y; Duensing S; Altevogt P; Klauck SM; Sültmann H
Oncotarget; 2017 Apr; 8(15):25115-25130. PubMed ID: 28445989
[TBL] [Abstract][Full Text] [Related]
15. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.
Kim JS; Roberts JM; Bingman WE; Shao L; Wang J; Ittmann MM; Weigel NL
Endocrinology; 2014 Sep; 155(9):3262-73. PubMed ID: 24926821
[TBL] [Abstract][Full Text] [Related]
16. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.
Dai Y; Desano J; Tang W; Meng X; Meng Y; Burstein E; Lawrence TS; Xu L
PLoS One; 2010 Dec; 5(12):e14153. PubMed ID: 21170316
[TBL] [Abstract][Full Text] [Related]
17. Retigeric acid B exhibits antitumor activity through suppression of nuclear factor-κB signaling in prostate cancer cells in vitro and in vivo.
Liu YQ; Hu XY; Lu T; Cheng YN; Young CY; Yuan HQ; Lou HX
PLoS One; 2012; 7(5):e38000. PubMed ID: 22666431
[TBL] [Abstract][Full Text] [Related]
18. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
Shao L; Kahraman N; Yan G; Wang J; Ozpolat B; Ittmann M
Prostate; 2020 Jan; 80(1):65-73. PubMed ID: 31614005
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
[TBL] [Abstract][Full Text] [Related]
20. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
